Margenza Market Report 2026

Margenza Market Overview

• The Margenza market growth in the historic period has been driven by increasing incidence of her2-positive breast cancer, expansion of oncology treatment centers • Market expansion is supported by increasing development of next-generation antibody therapies, rising investments in precision oncology • Growth Driver: Rising Incidence Of HER2-Positive Breast Cancer Drives Market Growth • North America was the largest region in 2025.

What Is Covered Under Margenza Market?

Margenza ( margetuximab-cmkb) is a monoclonal antibody medication that targets the human epidermal growth factor receptor 2 (HER2). It is approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, with at least one for metastatic disease. The main indication of margenza are breast cancer and gastric cancer. Breast cancer is a type of cancer that originates in the cells of the breast, typically in the ducts or lobules, and can spread to other parts of the body if not detected and treated early. It is available in various formulations, such as intravenous infusion and subcutaneous injection. It's distributed through different channels like hospitals, oncology clinics, and home healthcare services. Also, it is used by several end users, including adult patients and geriatric patients.

What Is The Margenza Market Growth Forecast?

The growth in the forecast period can be attributed to increasing development of next-generation antibody therapies, rising investments in precision oncology, expansion of home-based cancer care services, growing focus on treatment-resistant cancers, increasing demand for patient-specific biologic treatments. Major trends in the forecast period include increasing adoption of her2-targeted monoclonal antibodies, rising use of combination oncology therapies, growing focus on personalized cancer treatment regimens, expansion of advanced biologic manufacturing capabilities, enhanced emphasis on improved clinical outcomes.

Global Margenza Market Segmentation

1) By Indication: Breast Cancer, Gastric Cancer 2) By Formulation: Intravenous Infusion, Subcutaneous Injection 3) By Distribution Channel: Hospitals, Oncology Clinics, Home Healthcare Services, 4) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Margenza Market?

The increase in HER2-positive breast cancer is expected to propel the growth of the margenza market going forward. HER2-positive breast cancer refers to a type of breast cancer in which cancer cells have higher than normal levels of the HER2 protein on their surface. The increase in HER2-positive breast cancer is attributed to better detection and diagnosis through advanced screening technologies, genetic and environmental factors, an aging population, and hormonal and reproductive influences that may increase susceptibility to this subtype of cancer. Margenza is beneficial for HER2-positive breast cancer, targeting and blocking the HER2 protein, helping to slow down or stop the growth of cancer cells that overproduce this protein. For instance, in July 2025, according to a study published in The International Journal of Molecular Sciences, an US-based international peer-reviewed scientific journal, in 2022 there were about 2.3 million new cases and 670,000 deaths of breast cancer among women worldwide, with projections indicating that by 2050 the number of new cases and deaths will increase by 38% and 68% respectively. Therefore, an increase in HER2-positive breast cancer drives the clinical trial margenza industry. The rising healthcare expenditure is expected to propel the growth of the margenza market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, and infrastructure, including public and private spending on healthcare systems, equipment, and pharmaceuticals. The rise in healthcare expenditure is driven by factors such as aging populations, advancements in medical technologies, increased prevalence of chronic diseases, and growing demand for high-quality healthcare services. Higher healthcare budgets allow for greater investment in advanced and specialized treatments, including targeted therapies such as Margenza. As governments, private insurers, and individuals allocate more resources to healthcare, the affordability and availability of expensive cancer treatments improve. For instance, in September 2024, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, in 2022, U.S. healthcare spending increased by 4.1% in 2024, totaling $4.5 trillion, equating to $13,493 per capita. Therefore, rising healthcare expenditure will drive the growth of the margenza industry.

Key Players In The Global Margenza Market

Major companies operating in the margenza market are MacroGenics Inc.

What Are Latest Mergers And Acquisitions In The Margenza Market?

In October 2024, TerSera Therapeutics, LLC, a US-based pharmaceutical company, acquired rights to the breast cancer drug MARGENZA (margetuximab) from MacroGenics for an undisclosed amount. With this acquisition, TerSera Therapeutics aims to expand its oncology portfolio and provide a new treatment option for patients with HER2-positive breast cancer. MacroGenics is a US-based biotechnology company that manufactures antibody-based therapeutics for cancer treatment, including MARGENZA (margetuximab-cmkb).

Regional Insights

North America was the largest region in the margenza market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Margenza Market?

The margenza market consists of sales of margenza (margetuximab) injection, combination therapies, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Margenza Market Report 2026?

The margenza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the margenza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.